Literature DB >> 30244853

Favorable Outcome With Pemetrexed Treatment for Advanced BRAF-V600E-Positive Lung Adenocarcinoma in a Patient Followed up Over 8 Years.

Yoko Nakanishi1, Yoshiko Nakagawa2, Ichiro Tsujino3, Tetsuo Shimizu2, Noriaki Takahashi2, Shu Hashimoto2, Shinobu Masuda1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30244853     DOI： 10.1016/j.jtho.2018.05.010

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Clinicopathological aspects of V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small cell lung carcinoma in an Indian cohort: is there a difference?

Authors:  Ullas Batra; Shrinidhi Nathany; Mansi Sharma; Sakshi Mattoo; Anurag Mehta; Joslia T Jose
Journal:  Int J Mol Epidemiol Genet       Date:  2021-12-15

2.  Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1.

Authors:  Takuma Katano; Tsuneyuki Oda; Akimasa Sekine; Midori Sato; Takafumi Yamaya; Yozo Sato; Koji Okudela; Eri Hagiwara; Takashi Ogura
Journal:  Respir Med Case Rep       Date:  2020-05-01

3.  Non-small Cell Lung Cancer With Proto-Oncogene B-Raf V600E Presenting a Distinctive Clinical Course: A Case Report.

Authors:  Aosa Sasada; Tatsuya Yuba; Shinsuke Shiotsu; Taisuke Tsuji; Noriya Hiraoka
Journal:  Cureus       Date:  2022-03-11

4.  Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study.

Authors:  Lei Lei; Wen-Xian Wang; You-Cai Zhu; Xing-Xiang Pu; Yong Fang; Hong Wang; Wu Zhuang; Yin-Bin Zhang; Li-Ping Wang; Chun-Wei Xu; Mei-Yu Fang
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.